SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 14, 2026

EWTX

Edgewise Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3mo ago
Insider cluster: 2 insiders, $468K total
Actionable Insight • Neutral

Insider sales are routine post-vesting liquidity events, no bearish signal. Monitor EDG-7500 Phase 3 initiation in Q4 2026 as the primary catalyst. The $2.01B pro-forma cash position provides a multi-year runway; the Q2 miss is noise for a pre-revenue biotech.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

EWTX drug pipeline →

EDG-7500

◆ Mixed Named in this insider cluster
Impact
Phase
Phase 2
Time to market
4-6 years (Phase 2 completed; Phase 3 starting Q4 2026; if successful, NDA filing likely 2029-2030 at earliest)
Next catalyst
None dated

What to watchEdgewise is now a cardiovascular-focused single-product company after selling its muscular dystrophy business to Servier for $1.55B upfront. EDG-7500's Phase 2 safety data (no LVEF drops below 50% across all patients) is a genuine differentiator, but efficacy against BMS's approved Camzyos and Cytokinetics' pending aficamten remains unproven. Watch for Phase 3 start in Q4 2026 and any partnership/BD rumors for the program.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$44.04
T+0 close · Aug 14, 2026 · via day close
Latest settled
+5.65%
T+60 · $46.53
Vs SPY
+8.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $44.04entry
  2. T+1 · 3mo ago +0.16%α +0.83% · $44.11
  3. T+5 · 3mo ago +1.54%α +2.73% · $44.72
  4. T+20 · 2mo ago −0.93%α +1.05% · $43.63
  5. T+60 · 7d ago +5.65%α +8.60% · $46.53
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Kevin Koch and General Counsel John Moore sold a combined ~$468K in open-market sales on August 12, 2026, following the Q2 earnings miss and the close of the sevasemten sale to Servier. The sales are small relative to the $4.8B market cap (~0.01%) and are paired with large non-cash equity grants and derivative exercises, suggesting tax-related selling rather than a bearish signal. The cluster is neutral, the dollar value is trivial and the sales are likely liquidity-driven post-vesting.

Key Financial Metrics

Direction
selling
Total Value
$1.0M
Insiders
2

Key Facts

  • CEO Kevin Koch sold 18,000 shares for ~$785K total (two trades on Aug 12 at ~$43.64-$44.33)
  • General Counsel John Moore sold 5,016 shares for ~$220K total (four trades on Aug 12 at ~$43.80-$44.50)
  • Both executives received large non-cash equity grants (Koch: 300,000 shares; Moore: 97,500 shares) on the same day
  • Total open-market sales of ~$1.0M represent ~0.02% of $4.8B market cap, well below materiality threshold
  • Q2 2026 net loss of -$0.53/share missed consensus by 12.2%; company completed sevasemten sale for $1.55B upfront
  • Company pivoting to pure-play cardiovascular focus with EDG-7500 Phase 3 start planned Q4 2026

Financial Impact

Total insider open-market sales of ~$1.0M, or ~0.02% of market cap, immaterial

dilution

Risk Factors

  • Pre-revenue company with widening operating losses as it funds cardiovascular pipeline
  • EDG-7500 Phase 3 data risk, no approved products
  • Potential further dilution if cash burn accelerates before revenue generation

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
84% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-EWTX-1786774555208

Track record

14 reports on EWTX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today 144 Neutral 1/10 Entry price pending
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $44.09 Now $43.68 −0.93% settles Feb 12
  3. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
  4. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
  5. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.68 Now $43.68 +15.92% settles Feb 1
  6. Aug 14, 202613w ago Insider Cluster Neutral 4/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
  7. Aug 14, 202613w ago Insider Cluster Neutral 3/10 Viewing Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
  8. Aug 6, 202614w ago 8-K Mixed 7/10 Entry $44.42 to $38.90 Now $43.68 −1.67% ▼ −12.43% −10.76% vs SPY
  9. Jul 13, 202618w ago 8-K Bullish 7/10 Entry $41.27 to $40.02 Now $43.68 +5.84% ▼ −3.03% −7.02% vs SPY
  10. Jun 1, 202624w ago 8-K Bullish 8/10 Entry $40.26 to $44.21 Now $43.68 +8.49% ▲ +9.81% +8.58% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens Wed (11h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 15, 2026